Publications: Ms Vesna Florijancic

Back to Search

(2019). Commentary on Terry et al., 10-Year Performance of Four Models of Breast Cancer Risk: A Validation Study. Lancet Oncol. 2019;20(4):504-17. Med One vol. 4, (2)

10.20900/mo.20190006

Nedjai B, Reuter C, Ahmad A, Banwait R, Warman R, Carton J, Boer S, Cuzick J et al.(2018). Molecular progression to cervical precancer, epigenetic switch or sequential model?. Int J Cancer

10.1002/ijc.31549

Huh WK, Joura EA, Giuliano AR, Iversen O-E, de Andrade RP, Ault KA, Bartholomew D, Cestero RM et al.(2017). Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet vol. 390, (10108) 2143-2159.

10.1016/S0140-6736(17)31821-4

Thorat MA, Cuzick J(2017). Preventing invasive breast cancer using endocrine therapy. Breast

10.1016/j.breast.2017.06.027

Lorincz AT, Nathan M, Reuter C, Warman R, THAHA MA, Sheaff M, Vasiljevic N, Ahmad A et al.(2017). Methylation of HPV and a tumor suppressor gene reveals anal cancer and precursor lesions. Oncotarget vol. 8, (31) 50510-50520.

10.18632/oncotarget.17984

CUZICK JM, Bartlett J, Ikhlaaq A, Regan MM, Sestak I, Mallon EA, Dell'Orto P, Thürlimannh B et al.(2017). HER2 status predicts for upfront AI benefit: a TRANS-AIOG meta-analysis of 12129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. European Journal of Cancer

10.1016/j.ejca.2017.03.033

Cuzick J(2017). Preventing invasive breast cancer using endocrine therapy. BREAST vol. 32, S7-S8.

10.1016/S0960-9776(17)30071-1

Back to Search